SCHEMBL5754027

SCHEMBL5754027

O=C(O)c1cc([N+](=O)[O-])cc2c(O)nc(Nc3ccc(Cl)c(Cl)c3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.49
▸ KMT2A Q03164 6/20 0.49
▸ MAPT P10636 3/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ RECQL P46063 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ PIN1 Q13526 4/20 0.48
▸ TYMS P04818 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ XDH P47989 1/20 0.41
▸ SLC22A12 Q96S37 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PIK3CB P42338 1/20 0.41
▸ PIK3CG P48736 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CASP6 P55212 1/20 0.40
▸ SERPINE1 P05121 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755610 0.89 MEN1 (0.47) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5752579 0.86 MEN1 (0.49) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5754693 0.85 TYMS (0.46) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5753186 0.85 PIN1 (0.45) MEN1KMT2AMAPTPIN1L3MBTL1
SCHEMBL5756017 0.85 MEN1 (0.46) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5756011 0.85 MEN1 (0.46) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5755373 0.84 KMT2A (0.48) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5754271 0.84 TYMS (0.44) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5756932 0.83 TYMS (0.45) MEN1KMT2AMAPTCYP3A4RECQL
SCHEMBL5755848 0.83 PIN1 (0.45) MEN1KMT2AMAPTCYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1218358-B1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2006-09-13 — — EP disclosed
EP-1218358-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS AstraZeneca AB (SE) 2002-07-03 — — EP disclosed
US-6399603-B1 QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY ASTRAZENECA AB (SE) 2002-06-04 — — US disclosed
WO-2001021598-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2001-03-29 — — WO disclosed
Send feedback